Back pain affects more than 80 percent of people and costs more than $100 billion annually in the U.S. But is the surgery cost effective? A study by researchers at Rush University Medical Center suggests that for patients with spinal stenosis, a laminectomy, or surgical removal of some soft bone and tissue, is a reasonable value. However, for patients with spinal stenosis with associated slipped vertebrae, the benefits of spinal fusion surgery may not be enough to offset costs.
More: continued here
Weight bearing exercise during adolescence seems to be the best for maintaining bone strength in older life, indicates a small study published ahead of print in the British Journal of Sports Medicine. The research team assessed the impact of exercise between the ages of 12 and 18 on preserving bone strength in later life among 46 women. The women were all aged from 52 to 73, and had already gone through the menopause.
More: continued here
The Centers for Disease Control and Prevention and the American College of Sports Medicine recommends at least 30 minutes of moderate-intensity physical activity on most days of the week in order to maintain and improve optimal health. This recommendation is especially important for older Americans, who can be less likely to fulfill this requirement, yet are more at risk for chronic diseases associated with aging.
More: continued here
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells and Celgene Corporation, today announced the publication of the ACE-011 Phase 1 clinical study demonstrating that ACE-011 increased biomarkers of bone formation, decreased biomarkers of bone resorption and increased hemoglobin levels in postmenopausal women.
More: continued here
Artificial bone marrow that can continuously make red and white blood cells has been created in a University of Michigan lab. This development could lead to simpler pharmaceutical drug testing, closer study of immune system defects and a continuous supply of blood for transfusions.
More: continued here
A new report demonstrates how a sensitive imaging technique gives scientists the upper hand in seeking out bacteria in chronic infections. Listeria monocytogenes is a type of pathogenic bacteria that can cause severe illness and death. Listeria outbreaks recently claimed twenty lives in Canada. Additionally, Listeria infection is the third most common cause of bacterial meningitis in newborns, and can cause abortion and stillbirth.
More: continued here
Head banging increases the risk of head and neck injury, but the effects may be lessened with reduced head and neck motion, head banging to lower tempo songs or to every second beat, and using protective equipment such as neck braces, finds a study in the Christmas issue published on bmj.com.
More: continued here
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions of either 500 mg or 1000 mg of Rituxan or placebo for up to two treatment courses in combination with a stable dose of MTX.
More: continued here
Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said that surgeons are experiencing excellent early results with its new Optetrak® CR Slope™ knee system. Introduced in Q4 2008, the patent-pending CR Slope design builds on the company’s flagship Optetrak knee system.
More: continued here
CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, CA) announced positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo.
More: continued here





